Thus, myriocin induced improvement in dyslipidemia and hepatic steatosis in our study may also be related to changes in NPC1L1, CD36 and FATP4 expression and alterations in lipid raft composition that reduce intestinal fatty acid and cholesterol uptake. This evidence concerns the gene NPC1L1 and metabolic syndrome.